Nanoparticles containing insoluble drug for cancer therapy

Biotechnology Advances

Volumn 32, Issue 4, 2014, Pages 778-788

  Guo, Shutao ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Calcium phosphate; Drug delivery; Gold nanoparticle; Lipid; Liposome; Nanocrystals; Nanoparticle; Polymer; SiRNA

Indexed keywords

BIOCHEMISTRY; CALCIUM PHOSPHATE; DRUG DELIVERY; LIPIDS; LIPOSOMES; NANOCRYSTALS; POLYMERS;

ENHANCED PERMEABILITY AND RETENTION EFFECT; GOLD NANOPARTICLES; NANOPARTICLE FORMULATION; PHARMACOKINETIC PROFILES; POLYMERIC NANOPARTICLES; SIRNA; SOLID LIPID NANOPARTICLE (SLN); TARGETED DRUG DELIVERY;

NANOPARTICLES;

BIOTECHNOLOGY; CANCER; DISEASE TREATMENT; DRUG; DRUG DEVELOPMENT; LIPID; NANOTECHNOLOGY; POLYMER; TUMOR;

ANTINEOPLASTIC AGENT; GOLD; LIPID; LIPOSOME; METAL NANOPARTICLE; NANOPARTICLE; POLYMER; SMALL INTERFERING RNA;

CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; NANOMEDICINE; PERMEABILITY; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GOLD; HUMANS; LIPIDS; LIPOSOMES; METAL NANOPARTICLES; NANOMEDICINE; NANOPARTICLES; PERMEABILITY; POLYMERS; RNA, SMALL INTERFERING;

EID: 84901983844     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2013.10.002     Document Type: Review

References (153)

1. Adams M.L., Lavasanifar A., Kwon G.S. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003, 92:1343-1355.
2. Amann L.C., Gandal M.J., Lin R., Liang Y., Siegel S.J. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res 2010, 27:1730-1737.
3. Auweter H., André V., Horn D., Lüddecke E. The function of gelatin in controlled precipitation processes of nanosize particles. J Dispers Sci Technol 1998, 19:163-184.
4. Auzenne E., Donato N.J., Li C., Leroux E., Price R.E., Farquhar D., et al. Superior therapeutic profile of poly-l-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 2002, 8:573-581.
5. Bala I., Hariharan S., Kumar M. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004, 21:387.
6. Bangham A., Horne R. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964, 8:660-668.
7. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
8. Battaglia L., Serpe L., Muntoni E., Zara G., Trotta M., Gallarate M. Methotrexate-loaded SLNs prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution. Nanomedicine 2011, 6:1561-1573.
9. Bhatt R., de Vries P., Tulinsky J., Bellamy G., Baker B., Singer J.W., et al. Synthesis and in vivo antitumor activity of poly (l-glutamic acid) conjugates of 20 (S)-camptothecin. J Med Chem 2003, 46:190-193.
10. Bolling C., Graefe T., Lubbing C., Jankevicius F., Uktveris S., Cesas A., et al. Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs 2006, 24:521-527.
11. Bruce J.Y., Eickhoff J., Pili R., Logan T., Carducci M., Arnott J., et al. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs 2012, 30:794-802.
12. Bunjes H., Drechsler M., Koch M.H., Westesen K. Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharm Res 2001, 18:287-293.
13. Cai S., Vijayan K., Cheng D., Lima E.M., Discher D.E. Micelles of different morphologies-advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery. Pharm Res 2007, 24:2099-2109.
14. Cartwright H. Pfizer becomes BIND therapeutics' second major nanomedicine collaborator. PharmaDeals Rev. 2013, 2013.
15. Chang E.I., Galvez M.G., Glotzbach J.P., Hamou C.D., El-ftesi S., Rappleye C.T., et al. Vascular anastomosis using controlled phase transitions in poloxamer gels. Nat Med 2011, 17:1147-1152.
16. Chen H., Khemtong C., Yang X., Chang X., Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011, 16:354-360.
17. Cheng J., Khin K.T., Jensen G.S., Liu A., Davis M.E. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem 2003, 14:1007-1017.
18. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
19. Chertok B., Moffat B.A., David A.E., Yu F., Bergemann C., Ross B.D., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29:487-496.
20. Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
21. Danhauser-Riedl S., Hausmann E., Schick H.D., Bender R., Dietzfelbinger H., Rastetter J., et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993, 11:187-195.
22. Danson S., Ferry D., Alakhov V., Margison J., Kerr D., Jowle D., et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004, 90:2085-2091.
23. De Waard H., Hinrichs W., Frijlink H. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J Control Release 2008, 128:179-183.
24. de Waard H., Grasmeijer N., Hinrichs W.L., Eissens A.C., Pfaffenbach P.P., Frijlink H.W. Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production. Eur J Pharm Sci 2009, 38:224-229.
25. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31:3694-3706.
26. Dromi S., Frenkel V., Luk A., Traughber B., Angstadt M., Bur M., et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007, 13:2722-2727.
27. Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., Kirpotin D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006, 66:3271-3277.
28. Duffaud F., Borner M., Chollet P., Vermorken J.B., Bloch J., Degardin M., et al. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer 2004, 40:2748-2752.
29. Dumortier G., Grossiord J.L., Agnely F., Chaumeil J.C. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006, 23:2709-2728.
30. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
31. Duncan R., Kopeckova-Rejmanova P., Strohalm J., Hume I., Cable H.C., Pohl J., et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer 1987, 55:165-174.
32. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y., Satchi R., et al. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J Control Release 2001, 74:135-146.
33. Elzoghby A.O., Samy W.M., Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012, 157:168-182.
34. Emerich D.F., Thanos C.G. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target 2007, 15:163-183.
35. Emerson D.L., Bendele R., Brown E., Chiang S., Desjardins J.P., Dihel L.C., et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 2000, 6:2903-2912.
36. Ernsting M.J., Murakami M., Undzys E., Aman A., Press B., Li S.D. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J Control Release 2012, 162:575-581.
37. Ernsting M.J., Tang W.L., MacCallum N.W., Li S.D. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012, 33:1445-1454.
38. Esmaeili F., Ghahremani M.H., Esmaeili B., Khoshayand M.R., Atyabi F., Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm 2008, 349:249-255.
39. Faisant N., Siepmann J., Benoit J. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci 2002, 15:355-366.
40. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
41. Fassas A., Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005, 46:795-802.
42. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
43. Fonseca C., Simoes S., Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002, 83:273-286.
44. Fritze A., Hens F., Kimpfler A., Schubert R., Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta Biomembr 2006, 1758:1633-1640.
45. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet 2003, 42:419-436.
46. Gao L., Zhang D., Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 2008, 10:845-862.
47. Gibson J.D., Khanal B.P., Zubarev E.R. Paclitaxel-functionalized gold nanoparticles. J Am Chem Soc 2007, 129:11653-11661.
48. Green M., Manikhas G., Orlov S., Afanasyev B., Makhson A., Bhar P., et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006, 17:1263-1268.
49. Guo S., Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J Nanomater 2011, 2011:11.
50. Hamaguchi T., Kato K., Yasui H., Morizane C., Ikeda M., Ueno H., et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007, 97:170-176.
51. Hartung G., Stehle G., Sinn H., Wunder A., Schrenk H.H., Heeger S., et al. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res 1999, 5:753-759.
52. Heldin C.-H., Rubin K., Pietras K., Östman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
53. Homsi J., Simon G.R., Garrett C.R., Springett G., De Conti R., Chiappori A.A., et al. Phase I trial of poly-l-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 2007, 13:5855-5861.
54. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4(128):128ra39.
55. Huang L., Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011, 13:507-530.
56. Hwu J.R., Lin Y.S., Josephrajan T., Hsu M.-H., Cheng F.-Y., Yeh C.-S., et al. Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. J Am Chem Soc 2008, 131:66-68.
57. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
58. Jain T.K., Morales M.A., Sahoo S.K., Leslie-Pelecky D.L., Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2005, 2:194-205.
59. Junghanns J.-U.A., Müller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008, 3:295.
60. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
61. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006, 62:3-16.
62. Kim D., Park S., Lee J.H., Jeong Y.Y., Jon S. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc 2007, 129:7661-7665.
63. Kim C.K., Ghosh P., Pagliuca C., Zhu Z.-J., Menichetti S., Rotello V.M. Entrapment of hydrophobic drugs in nanoparticle monolayers with efficient release into cancer cells. J Am Chem Soc 2009, 131:1360-1361.
64. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268:235-237.
65. Ko A.H., Tempero M.A., Shan Y.S., Su W.C., Lin Y.L., Dito E., et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 2013, 109:920-925.
66. Kohler N., Sun C., Wang J., Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005, 21:8858-8864.
67. Kojima T., Hashida M., Muranishi S., Sezaki H. Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C. J Pharm Pharmacol 1980, 32:30-34.
68. Kopeček J., Kopečková P., Minko T., Lu Z.-R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000, 50:61-81.
69. Koudelka S., Turanek J. Liposomal paclitaxel formulations. J Control Release 2012, 163:322-334.
70. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
71. Kulke M.H., Chan J.A., Meyerhardt J.A., Zhu A.X., Abrams T.A., Blaszkowsky L.S., et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2011, 68:293-300.
72. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 2010, 75:1-18.
73. Lalatsa A., Schätzlein A.G., Mazza M., Le T.B.H., Uchegbu I.F. Amphiphilic poly (l-amino acids)-new materials for drug delivery. J Control Release 2012, 161:523-536.
74. Lee J.-S., Seferos D.S., Giljohann D.A., Mirkin C.A. Thermodynamically controlled separation of polyvalent 2-nm gold nanoparticle-oligonucleotide conjugates. J Am Chem Soc 2008, 130:5430-5431.
75. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.-B., et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108:241-250.
76. Lee J.-L., Ahn J.-H., Park S.H., Lim H.Y., Kwon J.H., Ahn S., et al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs 2012, 30:1984-1990.
77. Lee M.J., Ye A.S., Gardino A.K., Heijink A.M., Sorger P.K., MacBeath G., et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149:780-794.
78. Leonard R.C., Williams S., Tulpule A., Levine A.M., Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 2009, 18:218-224.
79. Li C. Poly (l-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 2002, 54:695-713.
80. Li S.-D., Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta Biomembr 2009, 1788:2259-2266.
81. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008, 60:886-898.
82. Li C., Yu D.-F., Newman R.A., Cabral F., Stephens L.C., Hunter N., et al. Complete regression of well-established tumors using a novel water-soluble poly (l-glutamic acid)-paclitaxel conjugate. Cancer Res 1998, 58:2404-2409.
83. Li J., Chen Y.-C., Tseng Y.-C., Mozumdar S., Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010, 142:416-421.
84. Li J., Stayshich R.M., Meyer T.Y. Exploiting sequence to control the hydrolysis behavior of biodegradable PLGA copolymers. J Am Chem Soc 2011, 133:6910-6913.
85. Li J., Yang Y., Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release 2012, 158:108-114.
86. Lim W., Tan E., Toh C., Hee S., Leong S., Ang P., et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors. Ann Oncol 2010, 21:382-388.
87. Lin N.U., Parker L.M., Come S.E., Burstein H.J., Haldoupis M., Ryabin N., et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007, 25:369-375.
88. Liu J., Xiao Y., Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci 2004, 93:132-143.
89. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface modified drug nanoparticles. Google Patents; 1992.
90. Liversidge G.G., Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995, 125:91-97.
91. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
92. Makadia H.K., Siegel S.J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011, 3:1377-1397.
93. May J.P., Li S.D. Hyperthermia-induced drug targeting. Expert Opin Drug Deliv 2013, 10:511-527.
94. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196.
95. Micha J.P., Goldstein B.H., Birk C.L., Rettenmaier M.A., Brown J.V. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006, 100:437-438.
96. Miele E., Spinelli G.P., Miele E., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99.
97. Miller S.M., Wang A.Z. Nanomedicine in chemoradiation. Ther Deliv 2013, 4:239-250.
98. Mitra S., Gaur U., Ghosh P., Maitra A. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001, 74:317-323.
99. Muddana H.S., Morgan T.T., Adair J.H., Butler P.J. Photophysics of Cy3-encapsulated calcium phosphate nanoparticles. Nano Lett 2009, 9:1559-1566.
100. Muller R.H., Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004, 113:151-170.
101. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
102. Murakami M., Ernsting M.J., Undzys E., Holwell N., Foltz W.D., Li S.D. Docetaxel conjugate nanoparticles that target alpha-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res 2013, 73:4862-4871.
103. Negishi T., Koizumi F., Uchino H., Kuroda J., Kawaguchi T., Naito S., et al. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer 2006, 95:601-606.
104. Neuzillet C., Tijeras-Raballand A., Cros J., Faivre S., Hammel P., Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013.
105. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897, 19:930-934.
106. O'Brien M.E., Socinski M.A., Popovich A.Y., Bondarenko I.N., Tomova A., Bilynsky B.T., et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:728-734.
107. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
108. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
109. Park E.K., Kim S.Y., Lee S.B., Lee Y.M. Folate-conjugated methoxy poly (ethylene glycol)/poly (e{open}-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 2005, 109:158-168.
110. Peng X.-H., Qian X., Mao H., Wang A.Y. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008, 3:311.
111. Pietras K., Rubin K., Sjoblom T., Buchdunger E., Sjoquist M., Heldin C.H., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62:5476-5484.
112. Prabhakar U., Blakey D.C., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., et al. Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology. Cancer Res 2013, 73:2412-2417.
113. Ramchandani M., Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50: 50 implants. J Control Release 1998, 54:167-175.
114. Rösler A., Vandermeulen G.W., Klok H.-A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2001, 53:95-108.
115. Ross H., Bonomi P., Langer C., O'Brien M., O'Byrne K., Paz-Ares L., et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). J Clin Oncol 2006, 7039. [Meeting Abstracts].
116. Roy A.C., Park S.R., Cunningham D., Kang Y.K., Chao Y., Chen L.T., et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013, 24:1567-1573.
117. Sabbatini P., Aghajanian C., Dizon D., Anderson S., Dupont J., Brown J.V., et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 2004, 22:4523-4531.
118. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8:1112-1120.
119. Saito G., Swanson J.A., Lee K.-D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55:199-215.
120. Schluep T., Cheng J., Khin K.T., Davis M.E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 2006, 57:654-662.
121. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006, 12:1606-1614.
122. Schluep T., Hwang J., Hildebrandt I.J., Czernin J., Choi C.H., Alabi C.A., et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A 2009, 106:11394-11399.
123. Schmolka I.R. Poloxamers in the pharmaceutical industry 1991, CRC Press, Boca Raton, FL.
124. Scholer N., Krause K., Kayser O., Muller R.H., Borner K., Hahn H., et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2001, 45:1771-1779.
125. Seiden M.V., Muggia F., Astrow A., Matulonis U., Campos S., Roche M., et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 2004, 93:229-232.
126. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009, 34:1629-1636.
127. Shegokar R., Muller R.H. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010, 399:129-139.
128. Shi J., Votruba A.R., Farokhzad O.C., Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010, 10:3223-3230.
129. Singer J.W., Baker B., de Vries P., Kumar A., Shaffer S., Vawter E., et al. Poly-(l)-glutamic acid-paclitaxel (CT-2103)[XYOTAX™], a biodegradable polymeric drug conjugate. Adv Exp Med Biol 2004, 81-99. Springer.
130. Smith A. Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 1986, 30:215-220.
131. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70:1-20.
132. Straubinger R.M., Balasubramanian S.V. Preparation and characterization of taxane-containing liposomes. Methods Enzymol 2005, 391:97-117.
133. Sun B., Yeo Y. Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Curr Opin Solid State Mater Sci 2012, 16:295-301.
134. Sun C., Lee J.S., Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008, 60:1252-1265.
135. Svenson S. Clinical translation of nanomedicines. Curr Opin Solid State Mater Sci 2012, 16:287-294.
136. Svenson S., Wolfgang M., Hwang J., Ryan J., Eliasof S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 2011, 153:49-55.
137. Swathi G., Prasanthi N., Manikiran S., Ramarao N. Solid lipid nanoparticles: colloidal carrier systems for drug delivery. ChemInform 2012, 43.
138. Tagami T., May J.P., Ernsting M.J., Li S.D. A thermosensitive liposome prepared with a Cu(2)(+) gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy. J Control Release 2012, 161:142-149.
139. Tevaarwerk A.J., Holen K.D., Alberti D.B., Sidor C., Arnott J., Quon C., et al. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 2009, 15:1460-1465.
140. Tziomalos K., Athyros V.G. Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review. Int J Nanomedicine 2006, 1:129.
141. Valle J.W., Armstrong A., Newman C., Alakhov V., Pietrzynski G., Brewer J., et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 2011, 29:1029-1037.
142. Vauthier C., Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009, 26:1025-1058.
143. Veltkamp S.A., Witteveen E.O., Capriati A., Crea A., Animati F., Voogel-Fuchs M., et al. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res 2008, 14:7535-7544.
144. Vis A., Van Der Gaast A., Van Rhijn B., Catsburg T., Schmidt C., Mickisch G. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 2002, 49:342-345.
145. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
146. Von Hoff D., Ervin T.J., Arena F.P., Chiorean E.G., Infante J.R., Moore M.J., et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). 2013 ASCO Gastrointestinal Cancers Symposium 2012, 24-26. [abstract].
147. Wang Y., Grayson S.M. Approaches for the preparation of non-linear amphiphilic polymers and their applications to drug delivery. Adv Drug Deliv Rev 2012, 64:852-865.
148. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
149. Warnecke A., Fichtner I., Saß G., Kratz F. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm 2007, 340:389-395.
150. Xiong X.-B., Falamarzian A., Garg S.M., Lavasanifar A. Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery. J Control Release 2011, 155:248-261.
151. Xu Z.P., Zeng Q.H., Lu G.Q., Yu A.B. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006, 61:1027-1040.
152. Yang Y., Li J., Liu F., Huang L. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther 2011, 20:609-615.
153. Zhang Y., Kim W.Y., Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 2013, 34:3447-3458.